NMPA approves Mersa East Keytruda to treat metastatic squamous non-small cell lung cancer in combination with caplatinum or yew alcohol

today, the(http://(MSD) of TheOfMersannounc announced that China's National Drug Administration (NMPA) has approved the company's heavy-duty PD-1 inhibitor Keytruda, which is used in conjunction with caplatinum or yew alcohol, to treat patients with metastatic squamous non-small cell lung cancer (NSCLC)Currently, keytruda's combination with chemotherapy has been approved for first-line treatment of scaly and non-scaly NSCLC patients, and Keytruda monotherapy has been approved for first-line treatment to express PD-L1 in NSCLC patients (TPS-1%)At the esMO Asia 2019Conference in Singapore(http://, Moshadon published the medium-termanalysis data of the medium-termanalysis of the Chinese sub-group (including China Extended Queue)(
http:// in the phase 3 ClinicalTrial(http://) keynote-407 study, which was designed to assess the effectiveness of the combined chemotherapy of The plisding scaly n.Ccompared to the placebo combined chemotherapy 　　In the KEYNOTE-407 China Extended Study, the Paboli-Zuma mono-combination treatment group had a 56 percent lower risk of death than the pure chemotherapy group, with a total survival (OS) of 17.3 months vs 12.6 months, respectively 　　The Paboli-Zumamono-combination treatment group had a 68 percent lower risk of disease progression or death than the chemotherapy group alone, and the non-progressive survival (PFS) in both groups was 8.3 months vs 4.2 months, respectively 　　In the KEYNOTE-407 China Extended Study, the Pablo Zumamono-combination group had a 56 percent lower risk of death than the purely chemotherapy group, compared with 29 percent in the global study